Liu, Jun-Jie
Orlova, Natalia
Oakes, Benjamin L.
Ma, Enbo
Spinner, Hannah B.
Baney, Katherine L. M.
Chuck, Jonathan
Tan, Dan
Knott, Gavin J.
Harrington, Lucas B.
Al-Shayeb, Basem
Wagner, Alexander
Brötzmann, Julian
Staahl, Brett T.
Taylor, Kian L.
Desmarais, John
Nogales, Eva
Doudna, Jennifer A.
Article History
Received: 31 July 2018
Accepted: 31 December 2018
First Online: 4 February 2019
Change Date: 3 April 2019
Change Type: Correction
Change Details: In this Article, owing to issues with the first 30 nucleotides of the sgRNA, which run in the opposite direction, corrections have been made to the Protein Data Bank (PDB) accessions in the ‘Data availability’ section, and this also affects Figs. 3, 4, Extended Data Fig. 6, Supplementary Table 1 and Supplementary Video 1. The original Article has been corrected online. See the accompanying Amendment for further details.
Competing interests
: J.A.D., B.L.O., L.B.H., J.-J.L. and N.O. have filed a related patent on CasX mutations and guide RNAs described herein with the US Patent and Trademark Office. J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Intellia Therapeutics, Scribe Therapeutics and Mammoth Biosciences, and a Director of Johnson & Johnson. J.A.D. is a scientific advisor to Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Synthego, Metagenomi, Mammoth Biosciences and Inari. J.A.D. has research projects sponsored by Biogen and Pfizer. L.B.H. is a co-founder of Mammoth Biosciences. B.L.O. is a co-founder of Scribe Therapeutics.